Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (31-40 of 301) with videos related to

Pageof 31
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 23, 2015
When Does FDAMA Section 114 Apply? Ten Case StudiesPeter J Neumann, Cayla J Saret
Pharmacoeconomics|October 28, 2006
Economic evaluation in the US: what is the missing link?Peter J Neumann, Sean D Sullivan
Health Affairs (Project Hope)|June 10, 2015
Medicare's Interventions Coverage: The Authors ReplyJames D Chambers, Peter J Neumann
The New England Journal of Medicine|January 22, 2010
Medicare and medical technology--the growing demand for relevant outcomesPeter J Neumann, Sean R Tunis
The Synthesis Project. Research Synthesis Report|November 5, 2011
Cost savings and cost-effectiveness of clinical preventive carePeter J Neumann, Joshua T Cohen
Health Policy (Amsterdam, Netherlands)|October 10, 2009
Personalized medicine: factors influencing reimbursementLisa M Meckley, Peter J Neumann
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 13, 2012
The economics of mild cognitive impairmentPei-Jung Lin, Peter J Neumann
American Journal of Preventive Medicine|October 31, 2002
Do HEDIS measures reflect cost-effective practices?Peter J Neumann, Bat Sheva Levine
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 20, 2020
Analyzing the Cost Effectiveness of Policy Responses for COVID-19: The Importance of Capturing Social ConsequencesDavid Daeho Kim, Peter J Neumann
Fundamental & Clinical Pharmacology|November 30, 2005
Quality-adjusted life years: how useful in medico economic studiesCarmen A Brauer, Peter J Neumann
Pageof 31

Showing results (31-40 of 301) with videos related to

Sort By:
Pageof 31
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 23, 2015
When Does FDAMA Section 114 Apply? Ten Case StudiesPeter J Neumann, Cayla J Saret
Pharmacoeconomics|October 28, 2006
Economic evaluation in the US: what is the missing link?Peter J Neumann, Sean D Sullivan
Health Affairs (Project Hope)|June 10, 2015
Medicare's Interventions Coverage: The Authors ReplyJames D Chambers, Peter J Neumann
The New England Journal of Medicine|January 22, 2010
Medicare and medical technology--the growing demand for relevant outcomesPeter J Neumann, Sean R Tunis
The Synthesis Project. Research Synthesis Report|November 5, 2011
Cost savings and cost-effectiveness of clinical preventive carePeter J Neumann, Joshua T Cohen
Health Policy (Amsterdam, Netherlands)|October 10, 2009
Personalized medicine: factors influencing reimbursementLisa M Meckley, Peter J Neumann
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 13, 2012
The economics of mild cognitive impairmentPei-Jung Lin, Peter J Neumann
American Journal of Preventive Medicine|October 31, 2002
Do HEDIS measures reflect cost-effective practices?Peter J Neumann, Bat Sheva Levine
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 20, 2020
Analyzing the Cost Effectiveness of Policy Responses for COVID-19: The Importance of Capturing Social ConsequencesDavid Daeho Kim, Peter J Neumann
Fundamental & Clinical Pharmacology|November 30, 2005
Quality-adjusted life years: how useful in medico economic studiesCarmen A Brauer, Peter J Neumann
Pageof 31